ANTIANGIOGENIC THERAPY WITH THE USE OF ANTIBODIES AGAINST A NEW MOLECULAR TARGET

Description

Angiogenesis is the physiological process by which new blood vessels are generated from the existing vasculature. This process is strictly regulated and occurs during the early stages of embryonic development, being relegated in the adult in very specific processes. On the other hand, there are times when the control that modulates this process is lost, causing various pathologies or favoring their development in adults, generating pathologies, some of them serious, such as the particular case of tumor angiogenesis. Due to the relevance of the process, it is finely regulated by a balance between proangiogenic signals and antiangiogenic signals. The present invention relates to the use of an enzyme not previously described as a new target in antiangiogenic therapy and in particular to the use of antibodies against said enzyme as inhibitors of the angiogenesis process. Likewise, the invention relates to the application of said antibodies in the prevention and / or treatment of pathologies that occur with angiogenesis.

Advantages

It is key to provide a new molecular target and therapeutic treatments to inhibit all pathologies that promote angiogenesis. The present invention relates to the use of a new molecular target closely involved in the angiogenic process, and to the use of specific antibodies against said target as a therapy for diseases that present with unwanted or excessive angiogenesis.

Uses and Applications

The present invention is encompassed within the health sector, specifically in the pharmacological sector for therapeutics against unwanted or excessive angiogenesis.